Development of a novel blood-based biomarker for malignancy v1
Research type
Research Study
Full title
Development of a novel blood-based biomarker to allow for early detection of malignancy
IRAS ID
256176
Contact name
Gareth Jenkins
Contact email
Sponsor organisation
Swansea University
Duration of Study in the UK
2 years, 8 months, 30 days
Research summary
We are interested in developing a novel blood test that can be used as to pick up cancer at an early stage. We will be looking to recruit patients with all different tumour types as well as patients who don't have cancer but may have another serious illness. We are hoping to recruit from the Rapid Diagnostic Clinic at Neath Port Talbot Hospital.
Our test measures blood cell mutations, which we have shown are elevated in oesophageal cancer patients. The aim of this study is to correlate blood cell mutation levels with different cancer types. We would like to answer the following research question:
Does the PIG-A mutation test and other DNA damage endpoints distinguish cancer patients from non-cancer patients, therefore does it have the ability to be used as an early detection tool?REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
19/LO/0732
Date of REC Opinion
28 Jun 2019
REC opinion
Further Information Favourable Opinion